en English

RNAi Therapeutics Market by 2029

Increasing usage of RNAi therapeutics for the treatment of neurodegenerative disorders is expected to create new opportunities for the market

A brand-new class of drugs based on ribonucleic acid is known as RNA therapies (RNA). Target mRNA molecules are neutralized during the biological process known as RNA interference, and RNA molecules are then shown to impede gene expression or translation. Additionally, RNA interference (RNAi) is a group of short RNA-directed processes that inhibits the expression of genes in a sequentially-specific manner.

Request For a Sample Copy of This Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-rnai-therapeutics-market

Rising cases of chronic diseases

The rising rates of chronic diseases like cancer, cardiovascular conditions, and others will accelerate market expansion. The RNAi therapeutics market will be further fuelled by additional factors such as rising RNAi therapeutic approvals, advancements in the healthcare sector, rising R&D expenditures, and rising pharmaceutical company collaborations during the forecast period of 2023 to 2030.

Increasing collaborative activities

The increasing collaboration activities between drug distribution companies and contract research organizations (CROs) contribute to the growth of the RNAi therapeutics market. Arrowhead Pharmaceuticals Inc and Horizon Therapeutics plc announced a global collaboration and licence agreement for ARO-XDH, a previously undisclosed discovery-stage investigational RNA interference (RNAi) therapeutic being developed by Arrowhead as a potential treatment for people with uncontrolled gout, on June 21, 2021. This collaboration with Horizon also represents an expansion of Arrowhead Pharmaceuticals’ rapidly growing pipeline of investigational RNAi therapeutics based on the company’s proprietary Targeted RNAi Molecule (TRiMTM) platform.” In January 2016, Ionis Pharmaceuticals (previously Isis Pharmaceuticals) began a Phase-I study of ISIS-HBV-L Rx in collaboration with GSK Pharmaceuticals. This acquisition aims to treat Hepatitis B viral infection.


Increasing use of RNAi therapeutics

Increasing usage of RNAi therapeutics for the treatment of neurodegenerative disorders is expected to create new opportunities for the market. For instance, Silence Therapeutics’ mRNAi GOLD platform is designed to deliver gene-silencing medicine to specific liver cells in the body by combining siRNA molecules with chemical address tags called GaINAc, a naturally occurring sugar that binds specifically to liver cells. These RNAi molecules can then enter liver cells and silence disease-associated genes that are expressed there.

North America dominates the RNAi therapeutics market due to the growing geriatric population and innovative medical technology adoption. Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the rising health awareness among the people and increasing demand for advanced medical technology.

Some of the major players operating in the RNAi Therapeutics Market are Quark Software Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Rexahn Pharmaceuticals, Inc. (U.S.), Silence Therapeutics (U.K.), Arbutus Biopharma (U.S.), Benitec Biopharma (Australia), GSK plc (U.K.), OLIX PHARMACEUTICALS, INC. (South Korea), Sanofi (France), Alnylam Pharmaceuticals, Inc. (U.S.), Moderna Inc. (U.S.), Ionis Pharmaceuticals (U.S.) among others

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:- corporatesales@databridgemarketresearch.com